Usted buscó: inayotegemea (Suajili - Inglés)

protini kuu ya replicase-transcriptase ndio rna polymerase inayotegemea rna (rdrp).
the main replicase-transcriptase protein is the rna-dependent rna polymerase (rdrp).

fda imeidhinisha kipimo kinachotumia teknolojia ya uzalishaji ya asidi ya kinyuklia inayotegemea kipimo thabiti cha nyuzi joto badala ya pcr.
the fda has approved a test that uses isothermal nucleic acid amplification technology instead of pcr.

jambo la kupendeza ni kuwa, dawa ya nucleotide analogue remdesivir inafahamika kudidimisha uzalishaji wa cov kupitia uzuiaji wa eksoribonuklisi na rna polimerisi inayotegemea rna.
interestingly, the nucleotide analogue remdesivir is known to suppress cov replication through inhibition of this exoribonuclease and the rna-dependent rna polymerase.

huko kanada tarehe 16 aprili 2020, chuo kikuu cha waterloo cha shule ya kusomea dawa ilitangaza muundo wa chanjo iliyoteuliwa inayotegemea dna kama dawa ya kinyunyizio cha pua inayowezekana.
in canada on 16 april 2020, the university of waterloo school of pharmacy announced design of a dna-based vaccine candidate as a possible nasal spray.

protini zinazolengwa zaidi za sars-cov-2 ni protease kama papain, rna inayotegemea rna polymerase, helicase, protini s, na adp ribophosphatase.
of the most important sars-cov-2 target proteins are papain-like protease, rna dependent rna polymerase, helicase, s protein, and adp ribophosphatase.

australia na new zealand inazingatia programu kulingana na programu ya tracetogether ya singapoo na itifaki ya bluetrace. urusi inatarajia kuanzisha programu inayotegemea eneo ya wagonjwa wanaopatikana kuwa na covid-19 wanaoishi moscow, iliyoundwa kuhakikishwa kuwa hawatoki nyumbani.
both australia and new zealand are considering apps based on singapore's tracetogether app and bluetrace protocol.russia intends to introduce a geofencing app for patients diagnosed with covid-19 living in moscow, designed to ensure they do not leave home.

hadi machi2020, kulikuwa na chanjo moja ya mers (inayotegemea dna) iliyokamilisha majaribio ya awamu ya i ya kliniki kwa wanadamu, na zingine tatu zinaendelea, zote ambazo ni chanjo ya kuzuia virusi, virusi viwili ya dna (chadox1-mers, bvrs-gamvac), na mva-vectored (mva-mers-s).
as of march 2020, there was one (dna based) mers vaccine which completed phase i clinical trials in humans, and three others in progress, all of which are viral-vectored vaccines, two adenoviral-vectored (chadox1-mers, bvrs-gamvac), and one mva-vectored (mva-mers-s).